OSIMERTINIB for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 4,754 adverse event reports in the FDA FAERS database where OSIMERTINIB was used for Lung neoplasm malignant.
Most Reported Side Effects for OSIMERTINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 10,423 | 37.6% | 10,418 | 239 |
| Malignant neoplasm progression | 2,920 | 10.5% | 574 | 354 |
| Diarrhoea | 1,408 | 5.1% | 174 | 431 |
| Drug resistance | 1,026 | 3.7% | 139 | 98 |
| Fatigue | 819 | 3.0% | 102 | 231 |
| Rash | 772 | 2.8% | 79 | 212 |
| Decreased appetite | 706 | 2.5% | 138 | 273 |
| Drug ineffective | 627 | 2.3% | 144 | 111 |
| Dyspnoea | 621 | 2.2% | 158 | 327 |
| Nausea | 610 | 2.2% | 82 | 228 |
| Disease progression | 607 | 2.2% | 107 | 33 |
| Off label use | 576 | 2.1% | 115 | 124 |
| Interstitial lung disease | 573 | 2.1% | 221 | 305 |
| Metastases to central nervous system | 560 | 2.0% | 125 | 109 |
| Myelosuppression | 510 | 1.8% | 10 | 166 |
Other Indications for OSIMERTINIB
Non-small cell lung cancer (6,358)
Lung carcinoma cell type unspecified stage 0 (1,950)
Non-small cell lung cancer metastatic (1,056)
Lung adenocarcinoma (936)
Egfr gene mutation (695)
Product used for unknown indication (408)
Non-small cell lung cancer stage iv (404)
Neoplasm malignant (345)
Lung carcinoma cell type unspecified stage iv (330)
Lung adenocarcinoma stage iv (278)
Other Drugs Used for Lung neoplasm malignant
ERLOTINIB (9,207)
NIVOLUMAB (4,197)
PEMBROLIZUMAB (3,575)
CARBOPLATIN (3,487)
ALECTINIB (2,932)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)
ATEZOLIZUMAB (1,262)